News
It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.
Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...
U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...
According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...
The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...
The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...
Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback